SEP 2012

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/82503

Contents of this Issue


Page 24 of 103

OVER 15 MILLION PROCEDURES AND COUNTING Helping you take more of your patients beyond 20/20* Visit us at AAO Booth #3244. Only iLASIK Technology provides truly customized treatments to help you take more of your patients beyond 20/20. Scan this code or visit www.amo-ilasik.com/proven to learn how to bring proven technology, that's good enough for NASA, to your patients. *20/16 results delivered with excimer laser, clinical studies send to FDA via P930016 supplement 021. Laser assisted in-situ keratomileusis (LASIK) can only be performed by a trained ophthalmologist and for specifi ed reduction or elimination of myopia, hyperopia, and astigmatism as indicated within the product labeling. Laser refractive surgery is contraindicated for patients: a) with collagen vascular, autoimmune, or immunodefi ciency diseases; b) who are pregnant or nursing women; c) with signs of keratoconus or abnormal corneal topography; d) who are taking one or both of the following medications: Isotretinoin (Accutane) and Amiodarone hydrochloride (Cordarone). Potential side effects to laser refractive surgery may include glare, dry eye, as well as other visual anomalies. LASIK requires the use of a microkeratome that cuts a fl ap on the surface of the cornea, potential side effects may include fl ap related complications. Patients are requested to consult with their eye care professional and Patient Information Booklet regarding the potential risks and benefi ts for laser refractive surgery, results may vary for each individual patient. Restricted Device: U.S. Federal Law restricts this device to sale, distribution, and use by or on the order of a physician or other licensed eye care practitioner. U.S. Federal Law restricts the use of this device to practitioners who have been trained in its calibration and operation and who have experience in the surgical treatment and management of refractive errors. Please see brief statement on adjacent page. ©2012 Abbott Medical Optics Inc. iLASIK is a registered trademark owned by or licensed to Abbott Laboratories, its subsidiaries or affi liates. 2011. 2011.04.26-RF3357

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - SEP 2012